亚盛医药启动2亿美元ATM融资计划,加速奥雷巴替尼及Lisaftoclax商业化进程

财中社
Jul 19

7月19日,亚盛医药(06855)发布公告,宣布于2026年7月20日向美国证券交易委员会提交了一份F-3表格的注册声明,计划通过建议ATM计划按市价出售最多达2亿美元的美国存托股份。此次计划的实施将允许公司灵活控制股份的出售时间和数量,且不需要在香港进行公开发售。  根据公告,建议ATM计划将主要用于奥雷巴替尼及Lisaftoclax的商业化、正在进行的候选药物的临床试验、运营资金及一般企业用途...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10